The FDA expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co. Inc., and approved a new two-tablet regimen for the drug.
There is a ray of sunshine for beleaguered Tesaro as Japanese pharma giant Takeda Pharmaceutical struck a deal worth up to $340 million for Asian development and marketing rights for recently approved PARP inhibitor Zejula (niraparib).
Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.
Clovis Oncology announced topline results from a confirmatory Phase III ARIEL3 trial of Rubraca (ruparib) in platinum-sensitive ovarian cancer.
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.
Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca’s Lynparza versus standard chemotherapy, according to a late-stage trial.
As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.
As AstraZeneca continues to move its operations to new headquarters in Cambridge, England, the company quietly pushed back its timeline for a late-stage lung cancer trial.
AbbVie Inc. said its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.
The U.S. Food and Drug Administration approved Tesaro Inc.’s drug, Zejula (niraparib), for the treatment of recurrent ovarian cancer.